East Ocyon Bio Secures $4.2 Mn In Seed Funding To Advance Allogeneic Cell & Gene Therapies
East Ocyon Bio, an allogeneic cell & gene therapy (CGT) startup, closed a USD 4.2 million Seed round. The investment round was spearheaded by Aeravti Ventures and Micro Labs, marking a significant step toward the company’s mission of revolutionising access to cutting-edge therapies both in India and across the globe. The funds will be pivotal in advancing several key initiatives, including pre-clinical testing of CAR-NK and CAR-gamma delta T cell therapies, establishing a GMP manufacturing facility, and conducting Phase I clinical trials.Founded by Renu Kundu and Dinesh Kundu, East Ocyon Bio aims to transform India from a hub of affordable generic medicines to a global leader in innovative biotech solutions. The company said its vision is to enable the development of curative therapies for cancers, autoimmune disorders, and rare diseases, all created in India and introduced concurrently with international markets. Despite India’s dominance in affordable medicine production, groundbreak
